IBDEI2YN ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47248,1,3,0)
 ;;=3^Opioid Use,Unspec,Uncomplicated
 ;;^UTILITY(U,$J,358.3,47248,1,4,0)
 ;;=4^F11.90
 ;;^UTILITY(U,$J,358.3,47248,2)
 ;;=^5003142
 ;;^UTILITY(U,$J,358.3,47249,0)
 ;;=Z79.891^^181^2359^1
 ;;^UTILITY(U,$J,358.3,47249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47249,1,3,0)
 ;;=3^Long Term Opiate/Opioid Analgesic Use
 ;;^UTILITY(U,$J,358.3,47249,1,4,0)
 ;;=4^Z79.891
 ;;^UTILITY(U,$J,358.3,47249,2)
 ;;=^5063342
 ;;^UTILITY(U,$J,358.3,47250,0)
 ;;=M15.8^^181^2360^51
 ;;^UTILITY(U,$J,358.3,47250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47250,1,3,0)
 ;;=3^Polyosteoarthritis,Other
 ;;^UTILITY(U,$J,358.3,47250,1,4,0)
 ;;=4^M15.8
 ;;^UTILITY(U,$J,358.3,47250,2)
 ;;=^5010767
 ;;^UTILITY(U,$J,358.3,47251,0)
 ;;=F07.0^^181^2360^41
 ;;^UTILITY(U,$J,358.3,47251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47251,1,3,0)
 ;;=3^Personality Change d/t Physiological Condition
 ;;^UTILITY(U,$J,358.3,47251,1,4,0)
 ;;=4^F07.0
 ;;^UTILITY(U,$J,358.3,47251,2)
 ;;=^5003063
 ;;^UTILITY(U,$J,358.3,47252,0)
 ;;=G62.9^^181^2360^50
 ;;^UTILITY(U,$J,358.3,47252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47252,1,3,0)
 ;;=3^Polyneuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,47252,1,4,0)
 ;;=4^G62.9
 ;;^UTILITY(U,$J,358.3,47252,2)
 ;;=^5004079
 ;;^UTILITY(U,$J,358.3,47253,0)
 ;;=F43.10^^181^2360^1
 ;;^UTILITY(U,$J,358.3,47253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47253,1,3,0)
 ;;=3^PTSD Unspec
 ;;^UTILITY(U,$J,358.3,47253,1,4,0)
 ;;=4^F43.10
 ;;^UTILITY(U,$J,358.3,47253,2)
 ;;=^5003570
 ;;^UTILITY(U,$J,358.3,47254,0)
 ;;=F43.12^^181^2360^2
 ;;^UTILITY(U,$J,358.3,47254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47254,1,3,0)
 ;;=3^PTSD,Chr
 ;;^UTILITY(U,$J,358.3,47254,1,4,0)
 ;;=4^F43.12
 ;;^UTILITY(U,$J,358.3,47254,2)
 ;;=^5003572
 ;;^UTILITY(U,$J,358.3,47255,0)
 ;;=G20.^^181^2360^39
 ;;^UTILITY(U,$J,358.3,47255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47255,1,3,0)
 ;;=3^Parkinson's Disease
 ;;^UTILITY(U,$J,358.3,47255,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,47255,2)
 ;;=^5003770
 ;;^UTILITY(U,$J,358.3,47256,0)
 ;;=I73.9^^181^2360^3
 ;;^UTILITY(U,$J,358.3,47256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47256,1,3,0)
 ;;=3^PVD,Unspecified
 ;;^UTILITY(U,$J,358.3,47256,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,47256,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,47257,0)
 ;;=I80.3^^181^2360^46
 ;;^UTILITY(U,$J,358.3,47257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47257,1,3,0)
 ;;=3^Phlebitis & Thrombophlebitis Lower Extremities,Unspec
 ;;^UTILITY(U,$J,358.3,47257,1,4,0)
 ;;=4^I80.3
 ;;^UTILITY(U,$J,358.3,47257,2)
 ;;=^5007845
 ;;^UTILITY(U,$J,358.3,47258,0)
 ;;=J02.9^^181^2360^42
 ;;^UTILITY(U,$J,358.3,47258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47258,1,3,0)
 ;;=3^Pharyngitis Acute,Unspec
 ;;^UTILITY(U,$J,358.3,47258,1,4,0)
 ;;=4^J02.9
 ;;^UTILITY(U,$J,358.3,47258,2)
 ;;=^5008130
 ;;^UTILITY(U,$J,358.3,47259,0)
 ;;=J18.9^^181^2360^49
 ;;^UTILITY(U,$J,358.3,47259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47259,1,3,0)
 ;;=3^Pneumonia,Unspec Organism
 ;;^UTILITY(U,$J,358.3,47259,1,4,0)
 ;;=4^J18.9
 ;;^UTILITY(U,$J,358.3,47259,2)
 ;;=^95632
 ;;^UTILITY(U,$J,358.3,47260,0)
 ;;=R09.1^^181^2360^48
 ;;^UTILITY(U,$J,358.3,47260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47260,1,3,0)
 ;;=3^Pleurisy
 ;;^UTILITY(U,$J,358.3,47260,1,4,0)
 ;;=4^R09.1
